Regulatory News:
The registration document ofVetoquinol (Paris:VETO) relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers ("the AMF") on April 29, 2019.
It can be read or downloaded on the websites of:
- Vetoquinol (www.vetoquinol.com)
- AMF (www.amf-france.org)
It is also available to the public free of charge upon simple request:
- by mail: Vetoquinol
Communication financière
Magny-Vernois BP 189 70204 Lure Cedex France
- by e-mail: relations.investisseurs@vetoquinol.com
- by phone: +33 (0)3 84 62 59 88
The registration document integrates among other:
- the report of the Board of directors on the corporate governance and on the internal control established upon provisions of article L. 225-37 of the French Commercial code;
- the management report;
- the declaration of extra-financial performance;
- the statutory auditors' reports;
- the information relative to the fees paid to the statutory auditors.
Next update: First half 2019 results, July 25, 2019 after market close
About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31, 2018 Vetoquinol employs 2,132 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com
VETOQUINOL 34 rue du Chêne Sainte Anne Magny-Vernois 70204 Lure Cedex France
www.vetoquinol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005655/en/
Contacts:
For more information, contact:
VETOQUINOL
Investor Relations
Fanny TOILLON
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com
KEIMA COMMUNICATION
Investor and Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr